Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 3/20 | 0.44 |
| ▸ | DPP4 | P27487 | 3/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28764608 | 0.83 | DPP4 (0.52) | PNMTDPP4LOXL2KDM4ESMN1; SMN2 | |
| SCHEMBL3146119 | 0.76 | LMNA (0.55) | PNMTDPP4LOXL2CYP2A6KDM4E | |
| SCHEMBL16542794 | 0.76 | PNMT (0.44) | PNMTDPP4LOXL2TAAR1CYP2A6 | |
| SCHEMBL263092 | 0.76 | PNMT (0.44) | PNMTDPP4LOXL2TAAR1CYP2A6 | |
| SCHEMBL8594383 | 0.76 | GABRA1 (0.41) | MEN1LMNATHRBBLMKMT2A | |
| SCHEMBL16935678 | 0.76 | PNMT (0.44) | PNMTDPP4LOXL2TAAR1CYP2A6 | |
| SCHEMBL28764723 | 0.74 | DPP4 (0.38) | PNMTDPP4TAAR1KDM4E | |
| SCHEMBL7518396 | 0.74 | PNMT (0.43) | PNMTDPP4LOXL2TAAR1CYP2A6 | |
| Hydrochloric Acid SCHEMBL8011172 | 0.74 | PNMT (0.43) | PNMTDPP4LOXL2TAAR1CYP2A6 | |
| Hydrochloric Acid SCHEMBL8833450 | 0.74 | LMNA (0.52) | PNMTDPP4LOXL2KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709469-B2 | P2X7 receptor antagonists and methods of use | ABBOTT LABORATORIES (US) | 2010-05-04 | — | — | US | disclosed |
| EP-1951689-A1 | P2X7 RECEPTOR ANTAGONISTS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007056046-A1 | P2X7 RECEPTOR ANTAGONISTS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105842-A1 | P2X7 receptor antagonists and methods of use | ABBVIE INC. | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105842-A1 | P2X7 receptor antagonists and methods of use | P2RX7, P2RX1, P2RX3 | PNMT 3312/4885DPP4 816/4885LOXL2 3946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.